Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
MARA rated glofitamab (COLUMVI) A (Strong) before HAS published CT opinion CT21596 on 18 March 2026. The A signal correctly predicted that reimbursement would be granted — HAS concluded SMR
MARA rated ruxolitinib cream (Opzelura) B++ (Marginal) before NICE published TA1140 on 17 March 2026. The B++ signal was driven by three decision-critical domains rated structurally weak: HRQoL data were
Link to the latest MARA Rating Executive SummaryThe MARA Rating for Leqembi (lecanemab) in early Alzheimer’s disease has been affirmed at B++ (Marginal) as of March 2026 following structured committee review. The rating band
NICE: MARA rated targeted-release budesonide (Kinpeygo) A (Strong) before NICE published TA1128 on 4 February 2026. The A grade correctly predicted a positive access outcome — NICE recommended budesonide as
Link to the full report here 1. Executive Summary MARA Rating has completed a formal surveillance review of CagriSema (cagrilintide + semaglutide) following publication of Phase 3 head-to-head results versus
MARA rated lecanemab (Leqembi) B++ (Marginal) before G-BA published Beschluss 7692 on 19 February 2026. The B++ grade correctly identified the marginal and uncertain zone — G-BA’s outcome of kein
MARA rated nivolumab (Opdivo) A (Strong) before NICE published TA1127 on 4 February 2026, recommending the drug for neoadjuvant plus adjuvant treatment of resectable NSCLC without EGFR or ALK alterations.
Lecanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for early Alzheimer’s disease. The complimentary MARA Rating® report evaluates Lecanemab’s market access prospects for the treatment of
Donanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for Alzheimer’s disease. Donanemab has been evaluated under the MARA Rating framework for its role in slowing cognitive
Aficamten — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for hypertrophic cardiomyopathy. This complimentary MARA Rating® report evaluates Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy